GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of hazard ratio is the most under-discussed thing on this board — 11 comments in the full submission. View in context.
94
c/trialwatch·submitted 4 months ago by u/first_hundred

hazard ratio is the most under-discussed thing on this board

Readoutbranch of 6 comments

hazard ratio is the most under-discussed thing on this board. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about. Relative risk reduction without the baseline rate is…

Read the full submission and all 11 comments →

This branch

6 comments, started 4 months ago
u/rohan_cardoso9 points·4 months ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/nayeli_fonseca3 points·4 months ago

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

replysharereportpermalink
u/sten_palacios2 points·4 months ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/rina_sobczak1 point·4 months ago

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

replysharereportpermalink
u/camila_vasquez1 point·4 months ago

Went looking for the registered protocol to see whether the endpoint had changed.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

replysharereportpermalink
u/first_hundredOP2 points·4 months ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →